THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.”VANCOUVER, Canada, April 07, 2026 (GLOBE NEWSWIRE) -- ...
The MarketWatch News Department was not involved in the creation of this content. -- $15 million upfront with a milestone-driven potential additional $15 million related to the Company's anticipated ...
Québec Innovative Materials (QIMCF) has announced an agreement with Research Capital Corporation (RCC) as the sole underwriter and bookrunner for a "bought deal" private placement, that consists of 16 ...
Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro, in vivo and non-human primate study results, that support development ...
-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The private placement also ...
$5M private placement financing with participation from new and existing stockholders and a strategic partner with deep obesity expertise significantly strengthens Company’s financial position as the ...
BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a ...
Kyle Samani, Managing Partner of Multicoin Capital, to Become Chairman of the Board of Directors, Effective Upon the Closing of the Private Placement Private Placement is the Largest Solana-focused ...
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: THIS PRESS RELEASE IS NOT BEING MADE IN AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES, CANADA, ...
$15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results